Compass Therapeutics Inc

Compass Therapeutics insider buys spark brief rally amid steep fall; leaders’ measured purchases hint cautious optimism, yet valuation concerns remain.

Compass Therapeutics insider buys signal undervaluation and potential rebound as key executives invest ahead of the proxy meeting, hinting at future upside.

Compass Therapeutics CFO buys 15,000 shares at $1.89, signaling confidence amid sharp price dip and heavy insider selling—what does this mean for investors?